Microbot Medical starts U.S. limited market release for LIBERTY
Microbot Medical began the U.S. limited market release of its LIBERTY endovascular robotic system after FDA clearance.
Evidence notes
- LIBERTY became commercially available in the U.S. through selected high-procedure-volume regions.
- The company said the launch followed commercial-team hiring and a third-party logistics partnership.
- The product gives The company a concrete offering for warehouse automation and material-handling workflows.
Company context
Microbot Medical develops LIBERTY, a compact single-use endovascular robotic system designed for remotely operated vascular access and navigation.